Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Shenyang Sunshine Pharmaceutical Co. Ltd. is currently navigating 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The prosecution is conducted by 1 distinct examiner and 1 distinct art unit. This concentration indicates that the company's current patenting activity is reviewed by a group at the patent office. The 1 pending office action represents the current engagement with the patent office for this portfolio.
The busiest examiner for this portfolio is STEPHENS, AMELIA CAROLE, who is responsible for 1 busiest examiner pending office action. As there is 1 distinct examiner involved, the outcome of the 1 pending office action is subject to the review of this individual. The presence of 1 distinct art unit confirms that the prosecution is confined to a technical silo. The 1 busiest examiner pending office action matches the 1 pending office action currently reported for the 1 distinct examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STEPHENS, AMELIA CAROLE | 1 | 75.0% | +50.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18722252 | ANTI-MASP-2 ANTIBODY, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | STEPHENS, AMELIA CAROLE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18722252 | ANTI-MASP-2 ANTIBODY, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | STEPHENS, AMELIA CAROLE | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18722252 | ANTI-MASP-2 ANTIBODY, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | STEPHENS, AMELIA CAROLE | 1645 | §102§103§112Other | Non-Final OA | — | Pending | Jun 20, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShenyang Sunshine Pharmaceutical Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Amelia Carole Stephens has the most, with 1 of Shenyang Sunshine Pharmaceutical Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
